Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
BMC Cancer. 2022 May 9;22(1):523. doi: 10.1186/s12885-022-09632-y.
Runt-related transcription factor 1 (RUNX1) is a vital regulator of mammalian expression. Despite multiple pieces of evidence indicating that dysregulation of RUNX1 is a common phenomenon in human cancers, there is no evidence from pan-cancer analysis.
We comprehensively investigated the effect of RUNX1 expression on tumor prognosis across human malignancies by analyzing multiple cancer-related databases, including Gent2, Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), the Human Protein Atlas (HPA), UALCAN, PrognoScan, cBioPortal, STRING, and Metascape.
Bioinformatics data indicated that RUNX1 was overexpressed in most of these human malignancies and was significantly associated with the prognosis of patients with cancer. Immunohistochemical results showed that most cancer tissues were moderately positive for granular cytoplasm, and RUNX1 was expressed at a medium level in four types of tumors, including cervical cancer, colorectal cancer, glioma, and renal cancer. RUNX1 expression was positively correlated with infiltrating levels of cancer-associated fibroblasts (CAFs) in 33 different cancers. Moreover, RUNX1 expression may influence patient prognosis by activating oncogenic signaling pathways in human cancers.
Our findings suggest that RUNX1 expression correlates with patient outcomes and immune infiltrate levels of CAFs in multiple tumors. Additionally, the increased level of RUNX1 was linked to the activation of oncogenic signaling pathways in human cancers, suggesting a potential role of RUNX1 among cancer therapeutic targets. These findings suggest that RUNX1 can function as a potential prognostic biomarker and reflect the levels of immune infiltrates of CAFs in human cancers.
runt 相关转录因子 1（RUNX1）是哺乳动物表达的重要调节剂。尽管有多项证据表明 RUNX1 失调是人类癌症的常见现象，但在泛癌分析中没有证据。
通过分析多个癌症相关数据库，包括 Gent2、肿瘤免疫估计资源（TIMER）、基因表达谱交互式分析（GEPIA）、人类蛋白质图谱（HPA）、UALCAN、PrognoScan、cBioPortal、STRING 和 Metascape，我们全面研究了 RUNX1 表达对人类恶性肿瘤肿瘤预后的影响。
生物信息学数据表明，RUNX1 在大多数这些人类恶性肿瘤中过表达，并且与癌症患者的预后显著相关。免疫组织化学结果表明，大多数癌症组织的细胞质呈中度阳性颗粒状，RUNX1 在包括宫颈癌、结直肠癌、神经胶质瘤和肾癌在内的四种肿瘤中的表达水平为中等。RUNX1 表达与 33 种不同癌症中癌症相关成纤维细胞（CAFs）的浸润水平呈正相关。此外，RUNX1 表达可能通过激活人类癌症中的致癌信号通路影响患者的预后。
我们的研究结果表明，RUNX1 表达与多种肿瘤患者的预后和 CAFs 的免疫浸润水平相关。此外，RUNX1 水平的升高与人类癌症中致癌信号通路的激活有关，表明 RUNX1 可能在癌症治疗靶点中发挥作用。这些发现表明 RUNX1 可以作为一种潜在的预后生物标志物，反映人类癌症中 CAFs 的免疫浸润水平。
